Form 4: Arcus Biosciences Director Patrick Machado Receives Significant Equity Grant

Arcus Biosciences, Inc. Director Patrick Machado was granted 13,300 restricted stock units and 38,300 stock options, aligning his interests with shareholders.

Summary

• Patrick Machado, a Director of Arcus Biosciences, Inc. (RCUS), was granted 13,300 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• These RSUs were granted at a price of $0 and will vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, or immediately upon a change in control of the company.
• Additionally, Mr. Machado was granted 38,300 stock options with an exercise price of $10.02 per share on June 10, 2025.
• These stock options will also vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, or immediately upon a change in control, and have an expiration date of June 9, 2035.
• Following these transactions, Mr. Machado beneficially owns 38,600 shares of Common Stock directly and 38,300 derivative securities (stock options) directly.
• A Power of Attorney was executed on June 10, 2025, by Patrick Machado, appointing several company executives and legal counsel as attorneys-in-fact to execute SEC filings on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard compensation practices that align director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The equity grants to Director Patrick Machado align his financial interests directly with those of the company's shareholders, incentivizing long-term value creation.
• The vesting schedule, tied to either a specific date or the next annual meeting, provides a clear timeline for the director's equity to become fully owned, promoting retention.
• The immediate vesting upon a change in control provides an incentive for the director to support transactions that could benefit shareholders.

Negatives

• The issuance of new equity (RSUs and potential exercise of options) could lead to a slight dilution of existing shareholder ownership over time, although this is standard practice for executive and director compensation.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of Arcus Biosciences' stock price.
• The vesting of these equity awards is contingent on Mr. Machado's continued service as a director until the specified vesting dates or a change in control event.

Future Outlook

The granted Restricted Stock Units and stock options are set to vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, or immediately upon a change in control of Arcus Biosciences, Inc. The stock options have an expiration date of June 9, 2035.

Industry Context

Equity grants to directors and executives are a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract, retain, and incentivize leadership by aligning their interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The grant of 13,300 Restricted Stock Units and 38,300 stock options to Patrick Machado, a Director of Arcus Biosciences, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor dilution from future RSU vesting and option exercise, but also benefit from increased alignment of director's interests with long-term company performance.
• Director (Patrick Machado): Receives significant equity compensation, incentivizing continued service and performance.

Next Steps

• Vesting of 13,300 Restricted Stock Units on the earlier of June 10, 2026, or the next annual meeting of stockholders, or upon a change in control.
• Vesting of 38,300 Stock Options on the earlier of June 10, 2026, or the next annual meeting of stockholders, or upon a change in control.
• Potential exercise of stock options by June 9, 2035, if the stock price is favorable.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Transaction, Stock Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Compensation, Patrick Machado